|4Feb 3, 4:20 PM ET

Bhatt Deepak 4

Research Summary

AI-generated summary

Updated

Bristol Myers (BMY) Director Deepak Bhatt Receives Award

What Happened

  • Deepak Bhatt, a director of Bristol Myers Squibb (BMY), was granted 3,996.367 deferred share units on 2026-02-01. The units are reported at $55.05 each for a total reported value of $220,000. The transaction is coded as an award/acquisition (derivative).

Key Details

  • Transaction date and price: 2026-02-01, 3,996.367 units at $55.05/unit, aggregate $220,000.
  • Transaction type: Award/Grant (derivative security — Deferred Share Units).
  • Shares owned after transaction: Not specified in this filing.
  • Filing: Reported to the SEC on 2026-02-03 (appears to be filed timely).
  • Footnotes:
    • F1: Each Deferred Share Unit will convert into one share of common stock upon settlement; units become settleable when the director leaves the board or at a future date previously specified by the reporting person.
    • F2: The award includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Context

  • These are deferred share units (a form of non-cash director compensation) rather than an open-market purchase. They represent a future right to receive shares and do not necessarily reflect an immediate change in market exposure.